Global Precision Medicine Market 2020-2030: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
September 30, 2020 03:04 ET | Research and Markets
Dublin, Sept. 30, 2020 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and...
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October
September 28, 2020 07:00 ET | Precision Biosciences
DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
Global $4.88 Bn CRISPR & Cas Genes Market to 2027: Opportunities in the Expanding Gene & Cell Therapy Area & Government Fund In Genomic R&D
September 21, 2020 05:18 ET | Research and Markets
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line...
Yield10 Bioscience Announces Second Quarter 2020 Financial Results
August 11, 2020 16:05 ET | Yield10 Bioscience, Inc.
WOBURN, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and six months ended June...
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
August 10, 2020 06:35 ET | LogicBio Therapeutics
– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform – – Enrollment to Start with Patients as Young as 3 Years Old, De-escalating...
LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
August 10, 2020 06:30 ET | LogicBio Therapeutics
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with...
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
January 10, 2020 07:05 ET | LogicBio Therapeutics
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –– Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –– Established research collaboration with...
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
January 10, 2020 07:00 ET | LogicBio Therapeutics
– LB-301 is a recombinant AAV vector with a UGT1A1 gene leveraging GeneRide™ genome editing platform for the treatment of Crigler-Najjar syndrome – – The collaboration agreement grants Takeda an...
LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates 
December 17, 2019 08:00 ET | LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial
November 12, 2019 07:15 ET | Precision Biosciences
DURHAM, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...